Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025
Skye Bioscience (Nasdaq: SKYE), a clinical-stage biotechnology company specializing in obesity and metabolic health disorders treatments, has scheduled its 2024 fourth quarter and full-year financial results announcement for March 20th, 2025. The company will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on the same day, following the release of its earnings press release after market close.
Investors can access the live webcast, earnings release, financial tables, and investor presentation through Skye's Investor Relations website. A replay and transcript will be made available after the call.
Skye Bioscience (Nasdaq: SKYE), un'azienda biotecnologica in fase clinica specializzata nel trattamento dell'obesità e dei disturbi metabolici, ha programmato l'annuncio dei suoi risultati finanziari per il quarto trimestre e per l'intero anno 2024 per il 20 marzo 2025. L'azienda ospiterà una conferenza telefonica alle 13:30 PT/16:30 ET nello stesso giorno, dopo la pubblicazione del comunicato stampa sui guadagni a mercato chiuso.
Gli investitori possono accedere alla diretta webcast, al comunicato sugli utili, alle tabelle finanziarie e alla presentazione per gli investitori tramite il sito web delle Relazioni con gli Investitori di Skye. Una registrazione e una trascrizione saranno rese disponibili dopo la chiamata.
Skye Bioscience (Nasdaq: SKYE), una compañía biotecnológica en etapa clínica especializada en tratamientos para la obesidad y trastornos de la salud metabólica, ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año completo 2024 para el 20 de marzo de 2025. La compañía llevará a cabo una conferencia telefónica a la 1:30 p.m. PT/4:30 p.m. ET el mismo día, tras la publicación de su comunicado de prensa de ganancias después del cierre del mercado.
Los inversores pueden acceder a la transmisión en vivo, al comunicado de ganancias, a las tablas financieras y a la presentación para inversores a través del sitio web de Relaciones con Inversores de Skye. Se hará disponible una repetición y una transcripción después de la llamada.
스카이 바이오사이언스 (Nasdaq: SKYE)는 비만 및 대사 건강 장애 치료를 전문으로 하는 임상 단계의 생명공학 회사로, 2024년 4분기 및 연간 재무 결과 발표를 2025년 3월 20일로 예정하고 있습니다. 회사는 같은 날 오후 1시 30분 PT/오후 4시 30분 ET에 시장 마감 후 수익 보도 자료 발표에 이어 전화 회의를 개최할 예정입니다.
투자자들은 스카이의 투자자 관계 웹사이트를 통해 실시간 웹캐스트, 수익 발표, 재무 테이블 및 투자자 발표에 접근할 수 있습니다. 통화 후에는 재생 및 전사가 제공될 예정입니다.
Skye Bioscience (Nasdaq: SKYE), une entreprise de biotechnologie en phase clinique spécialisée dans le traitement de l'obésité et des troubles de la santé métabolique, a programmé l'annonce de ses résultats financiers du quatrième trimestre et de l'année complète 2024 pour le 20 mars 2025. L'entreprise organisera une conférence téléphonique le même jour à 13h30 PT/16h30 ET, après la publication de son communiqué de presse sur les bénéfices après la fermeture du marché.
Les investisseurs peuvent accéder au webinaire en direct, au communiqué de presse sur les bénéfices, aux tableaux financiers et à la présentation pour les investisseurs via le site web des Relations avec les Investisseurs de Skye. Un enregistrement et une transcription seront disponibles après l'appel.
Skye Bioscience (Nasdaq: SKYE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Behandlung von Fettleibigkeit und Stoffwechselerkrankungen spezialisiert hat, hat die Bekanntgabe seiner Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2024 für den 20. März 2025 angesetzt. Das Unternehmen wird am selben Tag um 13:30 Uhr PT/16:30 Uhr ET eine Telefonkonferenz abhalten, nach der Veröffentlichung seiner Gewinnmitteilung nach Börsenschluss.
Investoren können über die Investor-Relations-Website von Skye auf das Live-Webcast, die Gewinnmitteilung, die Finanztabellen und die Präsentation für Investoren zugreifen. Eine Aufzeichnung und ein Transkript werden nach dem Anruf verfügbar sein.
- None.
- None.
SAN DIEGO, March 14, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Thursday, March 20th at 1:30 p.m. PT/4:30 p.m. ET to discuss its 2024 fourth quarter and full-year financial results. An earnings press release will be issued after the market closes on March 20th.
The live webcast of the call can be accessed at the Skye Investor Relations website, along with the company's earnings press release, financial tables, and investor presentation. Please join the call 5-10 minutes prior to the scheduled start time. Following the call, a replay and transcript will be available at the same website.
About Skye Bioscience
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.
CONTACTS
Investor Relations
ir@skyebioscience.com
(858) 410-0266
LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306
Media Inquiries
LifeSci Communications, Michael Fitzhugh
mfitzhugh@lifescicomms.com
(628) 234-3889
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “plans,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. These forward looking statements include, but are not limited to: statements regarding our product development, statements regarding the ability of nimacimab to treat obesity or related indications, and statements regarding the therapeutic potential of nimacimab. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Company’s periodic filings with the Securities and Exchange Commission, including in the “Risk Factors” section of Skye’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.
FAQ
When will Skye Bioscience (SKYE) release its 2024 financial results?
What time is Skye Bioscience's (SKYE) Q4 2024 earnings conference call?
Where can investors access Skye Bioscience's (SKYE) Q4 2024 earnings materials?
What therapeutic areas does Skye Bioscience (SKYE) focus on?
